CLAIMS:

1. Use of dexmedetomidine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating agitation associated with schizophrenia or bipolar disorder in an agitated human subject, wherein the medicament is to be administered to the oromucosa of the agitated human subject;
   wherein the human subject has a corrected QT interval using Fridericia's correction method (QTcF) of less than 470 msec; and
   wherein the subject is to be administered a first dose of dexmedetomidine or a pharmaceutically acceptable salt thereof, of 120 micrograms to 180 micrograms.

2. The use of claim 1, wherein the first dose of dexmedetomidine is about 120 micrograms of dexmedetomidine or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the first dose of dexmedetomidine is about 180 micrograms of dexmedetomidine or a pharmaceutically acceptable salt thereof.

4. The use of claim 2, wherein the use comprises a decrease in the agitation that is statistically significant at about 30 minutes following the administration.

5. The use of claim 3, wherein the use comprises a decrease in the agitation that is statistically significant at about 20 minutes following the administration.

6. The use of claim 1, wherein the medicament is in the form of a film.

7. The use of claim 6, wherein the medicament is to be administered sublingually.

8. The use of claim 6, wherein the medicament is to be administered buccally.

9. The use of claim 1, wherein the first dose of dexmedetomidine is about 120 micrograms of dexmedetomidine or a pharmaceutically acceptable salt thereof, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is in the form of a sublingual film, and wherein the use comprises a decrease in the agitation that is statistically significant at about 30 minutes following the administration.

10. The use of claim 1, wherein the first dose of dexmedetomidine is about 180 micrograms of dexmedetomidine or a pharmaceutically acceptable salt thereof, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is in the form of a sublingual film, and wherein the use comprises a decrease in the agitation that is statistically significant at about 20 minutes following the administration.

11. The use of claim 1, wherein the subject has a QTcF of less than 450 msec.

12. The use of claim 1, wherein the subject does not have an advanced heart block.

13. The use of claim 9, wherein the subject does not have an advanced heart block.

14. The use of claim 10, wherein the subject does not have an advanced heart block.

15. The use of claim 9, wherein the subject has a QTcF of less than 450 msec and wherein the subject does not have an advanced heart block.

16. The use of claim 10, wherein the subject has a QTcF of less than 450 msec and wherein the subject does not have an advanced heart block.

17. The use of claim 1, further comprising a second dose of dexmedetomidine or pharmaceutically acceptable salt thereof of 60 micrograms to 90 micrograms to be administered to the human subject 0.5 hours to 12 hours after administration of the first dose.

18. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is about 60 micrograms.

19. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is about 90 micrograms.

20. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 2 hours after administration of the first dose.

21. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 4 hours after administration of the first dose.

22. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 6 hours after administration of the first dose.

23. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 8 hours after administration of the first dose.

24. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 10 hours after administration of the first dose.

25. The use of claim 17, wherein the second dose of dexmedetomidine or pharmaceutically acceptable salt thereof is to be administered about 12 hours after administration of the first dose.